A very-low-calorie ketogenic diet normalises obesity-related enhanced levels of erythropoietin compared with a low-calorie diet or bariatric surgery

• Published in: Journal of endocrinological investigation 2024-11, Vol.47 (11), p.2701-2713
• Main Authors: Fernandez-Pombo, A., Lorenzo, P. M., Carreira, M. C., Gomez-Arbelaez, D., Castro, A. I., Primo, D., Rodriguez, J., Sajoux, I., Baltar, J., de Luis, D., Bellido, D., Crujeiras, A. B., Casanueva, F. F.
• Format: Article
• Language: English
• Subjects: Adult; Bariatric Surgery; Biomarkers - blood; Body Composition; Caloric Restriction - methods; Case-Control Studies; Diet, Ketogenic - methods; Endocrinology; Erythropoietin - blood; Female; Follow-Up Studies; Humans; Internal Medicine; Ketosis - blood; Ketosis - etiology; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Obesity - diet therapy; Obesity - metabolism; Obesity - surgery; Obesity, Morbid - blood; Obesity, Morbid - diet therapy; Obesity, Morbid - surgery; Original; Original Article; Weight Loss - physiology
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-024-02364-9

Purpose Nutritional ketosis synergistically with body-weight loss induced by a very-low-calorie ketogenic diet (VLCKD) has proven to be effective in improving obesity-related pathophysiology. Recently, growing attention has been focused on the relation between erythropoietin (EPO) and obesity. Thus, this study aims to investigate whether nutritional ketosis and weight loss induced by a VLCKD modify the circulating levels of EPO in patients with obesity in comparison with the effect of low-calorie diet (LCD) or bariatric surgery (BS). Methods EPO levels, iron status and body composition parameters were evaluated in 72 patients with overweight or obesity and 27 normal-weight subjects at baseline and after the three different weight-reduction therapies (VLCKD, LCD and BS) in 69 patients with excess body weight. β-hydroxybutyrate levels were also measured in the VLCKD group. The follow-up was established at 2–3 months and 4–6 months. Results It was found that EPO levels were higher in morbid obesity and correlated with higher basal weight, fat mass (FM) and fat-free mass (FFM) in the overall sample. High baseline EPO levels were also correlated with higher impact on the course of weight loss and changes in FM and FFM induced by the three weight-loss interventions. Furthermore, the VLCKD induced a decrease in EPO levels coinciding with maximum ketosis, which was maintained over time, while statistically significant changes were not observed after LCD and BS. Conclusion The obesity-related increased EPO levels are restored after VLCKD intervention at the time of maximum ketosis, suggesting a potential role of the nutritional ketosis induced by the VLCKD. Baseline EPO levels could be a biomarker of response to a weight-loss therapy. Graphical abstract